Effect of ozanimod on circulating leukocyte subtypes in patients with relapsing multiple sclerosis and comparison with healthy volunteers

被引：0
|
作者：
Harris, S. [1 ]
Maddux, R. [1 ]
Hoffmueller, U. [2 ]
Raschke, E. [2 ]
机构：
[1] Bristol Myers Squibb, Princeton, NJ USA
[2] Precis Med GmbH, Berlin, Germany
来源：
MULTIPLE SCLEROSIS JOURNAL | 2021年 / 27卷 / 2_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P659
引用
收藏
页码：567 / 567
页数：1
相关论文
共 50 条
  • [31] Baseline Cognition and Magnetic Resonance Imaging Measures of Patients With Relapsing Multiple Sclerosis in ENLIGHTEN: a Study of the Effect of Ozanimod on Cognitive Processing Speed
    DeLuca, J.
    Riolo, J. V.
    Cheng, C.
    Naismith, R. T.
    Wray, S.
    Bass, A. D.
    Fox, E.
    Riser, E.
    Chaudhry, B.
    Silva, D.
    Zivadinov, R.
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 49 - 50
  • [32] NFL as a predictor of GdE lesions in patients with relapsing multiple sclerosis treated with ozanimod in the phase 2 RADIANCE trial
    Harris, S.
    Vermersch, P.
    Montalban, X.
    Hartung, H-P
    Kappos, L.
    Southworth, H.
    Sheffield, J. K.
    Silva, D.
    Cohen, J. A.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 821 - 822
  • [33] Safety patterns with ozanimod in phase 3 and open-label extension trials in patients with relapsing multiple sclerosis
    Selmaj, K. W.
    Ziemssen, T.
    Comi, G.
    Hartung, H. P.
    Singal, M.
    Thorpe, A.
    Riolo, J. V.
    Cheng, C. Y.
    Sheffield, J. K.
    Krakovich, A.
    Vermersch, P.
    Cree, B. A. C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 324 - 324
  • [34] A Post Hoc Analysis of Immunoglobulin Levels in Patients with Relapsing Multiple Sclerosis Treated with Ozanimod in Phase 3 Trials
    Harris, S.
    Southworth, H.
    Sheffield, J. K.
    Maddux, R.
    Cohen, J.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (1_SUPPL) : 93 - 94
  • [35] Ozanimod Demonstrates Efficacy and Safety in a Phase 3 Trial of Relapsing Multiple Sclerosis (SUNBEAM)
    Comi, Giancarlo
    Arnold, Douglas L.
    Cree, Bruce A. C.
    Kappos, Ludwig
    Selmaj, Krzysztof W.
    Bar-Or, Amit
    Steinman, Lawrence
    Hartung, Hans-Peter
    Montalban, Xavier
    Havrdova, Eva K.
    Sheffield, James K.
    Raghupathi, Kartik
    Cohen, Jeffrey A.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 20 - 21
  • [36] Effect of fingolimod on multiple sclerosis severity score (MSSS) in patients with relapsing multiple sclerosis
    Montalban, X.
    Reder, A. T.
    Cohen, J.
    Ritter, S.
    Tomic, D.
    Meier, D. Piani
    Kappos, L.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 645 - 645
  • [37] Ozanimod demonstrates efficacy and safety in a phase 3 trial of relapsing multiple sclerosis (SUNBEAM)
    Comi, G.
    Kappos, L.
    Selmaj, K. W.
    Bar-Or, A.
    Arnold, D. L.
    Steinman, L.
    Hartung, H. -P.
    Montalban, X.
    Havrdova, E.
    Cree, B. A. C.
    Sheffield, J. K.
    Raghupathi, K.
    Cohen, J. A.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 73 - 74
  • [38] Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program
    Selmaj, Krzysztof W.
    Cohen, Jeffrey A.
    Comi, Giancarlo
    Bar-Or, Amit
    Arnold, Douglas L.
    Steinman, Lawrence
    Hartung, Hans Peter
    Montalban, Xavier
    Havrdova, Eva Kubala
    Cree, Bruce A. C.
    Minton, Neil
    Sheffield, James K.
    Ding, Ning
    Kappos, Ludwig
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 51
  • [39] Hepatic Safety of Ozanimod in Ulcerative Colitis and Relapsing Multiple Sclerosis Phase 3 Trials
    Rubin, David T.
    Caldera, Freddy
    Cohen, Jeffrey
    Zeuzem, Stefan
    Cheng, Chun-Yen
    Ather, Shabana
    Charles, Lorna
    Sheffield, James K.
    Dignass, Axel
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S581 - S581
  • [40] Synthesis of Matching-Adjusted Indirect Comparisons of Ozanimod for Relapsing Remitting Multiple Sclerosis
    Paul, D.
    Swallow, E.
    Patterson-Lomba, O.
    Branchcomb, T.
    Gomez-Lievano, A.
    Liu, J.
    Dua, A.
    McGinley, M.
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 47 - 47
12345